Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Efrat Luttwak

assistant professor

Memorial Sloan Kettering Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

About

Efrat Luttwak is an assistant professor at Memorial Sloan Kettering Cancer Center, USA. Her research focuses on the treatment and outcomes of various lymphomas, including insights derived from CAR T-cell therapy. Recent publications highlight advancements in morphology analysis for myelodysplasia and the implications of cancer cachexia in treatment responses.

Articles (17)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (6)

Akshay S Bedmutha

Assistant Professor

Emory University

UNITED STATES

View details

Yasmin Karimi

University of Michigan

UNITED STATES

View details

Maximilian Merz

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Marion Subklewe

LMU University Hospital

GERMANY

View details

Giulio Cassanello

Faculty

Ospedale San Raffaele

ITALY

View details

Dahlia Sano

Assistant professor

Karmanos Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Efrat Luttwak

Research Interests

Explore related searches

About

Articles (17)

Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma

Hattrick against Lymphoma with Trispecific CAR T Cells

Immunoglobulin replacement after chimeric antigen receptor T‐cell therapy in large B‐cell lymphoma with hypogammaglobulinaemia: Secondary Center for International Blood and Marrow Transplant Research analysis

Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma

SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers

Next‐generation morphology, a novel multilayer morphometric digital analysis, reveals both the basic topology and new trends of myelodysplasia of peripheral blood specimens

Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis

Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes

Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients

Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy

Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

Lymphoproliferative disease detected by breast cancer screening

Collaborators (6)

Akshay S Bedmutha

Yasmin Karimi

Maximilian Merz

Marion Subklewe

Giulio Cassanello

Dahlia Sano

Make your next move.